Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy

Completed · Phase 4

Conditions studied: Dry Eye Syndromes

In brief

The purpose of this study is to evaluate the effect of topical cyclosporine ophthalmic solution 0.05% (Restasis, Allergan) on the signs and symptoms of dry eye in patients undergoing LASIK or photorefractive keratectomy (PRK).

Key facts

Study ID

NCT00349440

Run by

Innovative Medical

People needed

93

Starts

2006-09-01

Expected to finish

2008-09-01

Last updated by the study team

2008-09-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females > 18 years old
• Mild-moderate symptoms of dry eye prior to surgery
• Scheduled to undergo bilateral LASIK or PRK
• Likely to complete all study visits and able to provide informed consent

You may not qualify if…

• Prior use of topical cyclosporine within the last 1 year
• Known contraindications to any study medication or ingredients
• Female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females.
• Ocular disorders
• Active ocular diseases or uncontrolled systemic disease
• Active ocular allergies

Where it is running

• Southeastern Laser and Refractive Surgery — Greensboro, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.